A new generation of ONLINE assays has been developed that offers improved performance and enhanced ease of use. This family of assays is being applied to both the COBAS INTEGRA and Roche/Hitachi line of analyzers. The four ONLINE DAT II assays that were evaluated included cocaine (benzoylecgonine) (BE), methadone (MDN), opiates (OP), and tetrahydrocannabinol (THC). The BE assay has a dual cutoff (150/300 ng/mL) with a dynamic range from 0 to 5000 ng/mL. The MDN assay has a cutoff of 300 ng/mL with a dynamic range from 0 to 2000 ng/mL. The opiates assay has a 300 ng/mL cutoff with a 0 to 2000 ng/mL range and a 2000 ng/mL cutoff with a 0 to 8000 ng/mL range. The THC assay has 20, 50, and 100 ng/mL cutoffs with 0 to 100, 0 to 300, and 0 to 300 ng/mL dynamic ranges, respectively. The ranges of the intraassay precision (coefficients of variation for n = 20) run in the semiquantitative mode are 2.3-7.5% for BE, 2.0-3.8% for MDN, 1.9-4.2% for OP, and 3.9-5.2% for THC. The intra-assay qualitative precision for all of the assays as calculated from absorbance values is generally higher than that of the intra-assay semiquantitative precision at the cutoff. The qualitative precision ranges between 0.4% and 3.1%. The standard curve stability defined for the COBAS INTEGRA systems for these reagents ranges from 35 to 68 days. The clinical sensitivity and specificity were compared to the OnLine generation I and CEDIA | immunoassays, as well as gas chromatography-mass spectrometry (GC-MS). The results indicate that for each assay, the sensitivity and specificity were the same or greater when compared to the other two immunoassay technologies. The results of each assay also correlated very well (> 99%) when compared with GC-MS.
Introduction
Several technologies currently exist on a variety of automated analyzers for the detection of drugs of abuse using various ira-. Author to whom correspondence should be addressed.
munoassay methods and formats. The Abuscreen OnLine assays for drugs of abuse testing (DAT) were launched in 1991. This technology is based on the kinetic interaction of microparticles in solution (KIMS) and is known for its steep dose response curves around the cutoff of the assay. At the time of launch, the OnLine assays represented the second nonradio isotopic assay testing system for DAT to be used on routine chemistry analyzers. Over the years, it has gained in popularity and is widely used in both hospital and reference laboratories (1) (2) (3) (4) (5) .
In response to growing and changing market demands of higher analytical performance and greater ease of use, ON-LINE II has been developed. This second-generation technology incorporates a number of new features addressing many aspects of importance to toxicologists and laboratory staff. This was accomplished by modifying the original KIMS technology by coupling the antibody to the microparticle surface and keeping a multivalent drug-conjugate in solution ( Figure 1 ). The original OnLine KIMS technology placed the drug conjugates on the bead surface, while the antibody remained free in solution.
The characteristics of distinguishing a positive sample from a negative sample remain the same. In the absence of free drug, the antibody-microparticle conjugate binds to the multivalent drug-conjugate causing agglutination of the microparticles. This agglutination process can be monitored spectrophotometrically (6) . The larger the agglutinated complex the more the light is scattered. The result is a net absorbance of the solution. Free drug in the sample inhibits the noted reaction, resuiting in smaller aggregates. The higher the concentration of free drug the less the light is scattered, resulting in a lower absorbance of the solution. The relationship between the agglutination complex and the amount of light scattered is proportional to r 6, where r is the radius of the complex. It is because of this relationship that microparticle-based assays can exhibit a high degree of accuracy throughout the range of the dose-response curve. The reversal of the binding reagents in which the immunoreactive component is bound to the microparticle, as well as the use of new monoclonal antibodies, has significantly changed a number of analytical and clinical characteristics of the original system. In addition, the compatibility of these reagents with various instruments has been greatly improved.
This report reviews the changes in the ONLINE KIMS technology and evaluates the performance characteristics of the benzoylecgonine (BE)-II, tetrahydrocannabinol (THC)-II, methadone (MDN)-II, and opiates (OP)-II assays on the COBAS INTEGRA and Roche/Hitachi analyzers. These four assays were the first to be developed in the new format and were available at the time of the study. Analytical characteristics, on-board stability, and clinical performance studies are presented. This performance is mainly compared to that of the original OnLine assays, as well some performance characteristics of other DAT assays that are commercially available.
Experimental

Biological samples
Clinical urine specimens were obtained from NWT Laboratories (Salt Lake City, UT), Laboratory Corporation of America (Raritan, N J), and ElSohly Laboratories (Oxford, MS) where they were screened by EMIT or OnLine. Specimens positive for a particular drug(s) were confirmed by gas chromatography-mass spectroscopy (GC-MS), according to the standard operating procedure of the laboratory. These specimens were stored at -20~ for periods of up to two years. Samples negative for all drugs were also obtained from a reference laboratory where they were negative by an EMIT screen or an OnLine screen. These negative samples were obtained within two weeks of collection and were stored at 4~ Any comparison of methods was done on the same aliquot and was subjected to analysis on the same day. Any discrepant samples by immunoassay (positive by immunoassay and negative by GC-MS, negative by immunoassay and positive by GC-MS, or positive by one immunoassay method and negative by another) were resolved by GC-MS. These discrepant samples were sent to an external lab for GC-MS analysis.
Clinical comparison
The ONLINE II reagents were compared with the original OnLine reagents on both the Roche/Hitachi 917 and COBAS IN-TEGRA 700.
The immunoassay cutoffs used for the clinical comparison were 20, 50, and 100 ng/mL of 11-nor-Ag-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) for THC, 150 and 300 ng/mL of benzoylecgonine for BE, 300 ng/mL of methadone parent for MDN, and 300 and 2000 ng/mL of morphine for OP. The GC-MS criteria for confirmation were 15 ng/mL of THC-COOH for the THC, 100 ng/mL of benzoylecgonine for BE, 300 ng/mL methadone parent for MDN, and 300 ng/mL of morphine or codeine for OP. Any discrepant samples by immunoassay or original GC-MS were sent out for an additional GC-MS confirmation.
Materials
Most of the chemicals used for cross-reactivity studies were obtained from Sigma Biochemicals and Reagents (St. Louis, MO). Cannabinoid metabolites were obtained from EISohly Laboratories, Inc.; Abuscreen OnLine and ONLINE II reagents, multianalyte calibrators, and multianalyte controls were provided by Roche Diagnostics Corporation (Indianapolis, IN) (6) (7) (8) (9) (10) (11) (12) (13) (14) . The COBAS INTEGRA and Roche/Hitachi analyzers from Roche Diagnostics Corporation were used according to manufacturer's instructions.
Methods
Precision. Precision was assessed by running each calibrator and control from the ONLINE II calibrator and control sets 20 times for each of five days. The ONLINE II calibrator sets (I and II) consisted of four to six levels of drug (Tables I and II) . For the precision study, the zero and highest calibrator were not run. Inter-and intra-assay precision were calculated in both the quantitative and absorbance mode. The results were expressed as a coefficients of variation (%cv).
Analytical limit of detection (LOD-A).
The LOD-A was determined by running the zero calibrator 21 times in the absorbance mode. The mean and standard deviation (SD) were calculated from these data. The average minus two SDs was then read off a linear regression line that was drawn between the average zero and first calibrator. The concentration of the drug was interpolated off the x-axis (15) .
Clinical LOD. The LOD was estimated by running 100 drug-free urine specimens as samples in each of the respective assays and calculating the average and SD. The LOD was defined as the mean value (ng/mL) of the 100 samples + 2 SD units (15) .
Standard curve stability. Standard curve stability was determined by running a standard curve on day zero, followed by running the + 25% of the cutoff controls each week. The reagents were stored on the instrument throughout the study, and each of the controls was run in triplicate at each time point. The stability was considered to have failed if any one of the measurements was negative for the positive control or positive for the negative control.
Carryover. The likelihood of carryover from a positive to negative sample was determined by assaying high (H) concentration samples (100 times the cutoff concentration) followed by low (L) concentration samples (zero concentration of drug). The sequence of the samples run was as follows: H1H2H3L1L2L3IAL5. The percent carryover was calculated as (L1 -L5)100/C = % carryover Eq. 1
where C = the cutoff concentration. lnterferants. The effect of interfering substances on the assay performance was assessed by preparing samples at the cutoff concentration of the assay with common interferants or adulterants. This was accomplished by adding the interfering substance to drug-free urine at twice the concentration indicated in Table III . These samples were then diluted 1:1 with drug-containing urine at twice the cutoff concentration of the assay, which resulted in a sample with drug concentrations at the respective cutoffs. The samples were then run in the assay on the same day, and the results were expressed as a percent recovery (Table III) .
Results
Standard curve
Typical calibration curves for the cannabinoid, cocaine, MDN, and OP assays were generated on the Roche/Hitachi 917 analyzer ( Figure 2 ). The THC-II assay has been designed to generate three separate curves that have been optimized to the 20, 50, and 100 ng/mL cutoffs. These cutoffs are the most commonly used levels for determining THC in urine. This was accomplished by adjustment of the sample size to 9, 5, and 4 pL, respectively. Each cutoff assay has a five-point calibration curve. The 20-ng/mL cutoff assay uses standards at 0, 10, 20, 40, and 100 ng/mL. The 50 ng/mL cutoff uses standards at 0, 20, 50, 100, and 300 ng/mL, and the 100 ng/mL cutoff assay uses standards at 0, 50, 100, 200, and 300 ng/mL. The BE-II assay was designed to have two cutoffs (150 and 300 ng/mL) read off the same standard curve. The addition of the 150 ng/mL cutoff to the BE-U assay is in response to pending Federal drug testing recommendations on lowering the cutoff from 300 to 150 ng/mL. The curve is generated with a 6-point calibration and uses standards of 0, 75, 150, 300, 1000, and 5000 ng/mL. The MDN-II assay was optimized with a 300 ng/mL cutoff and has a 5-point curve with calibrators at 0, 150, 300, 600, and 2000 ng/mL Finally, the OP-II assay was designed to generate two standard curves that have been optimized to 300 and 2000 ng/mL cutoffs. The OP-I1300-ng/mL assay uses a 6-point calibration with standards at 0, 150, 300, 600, 1000, and 2000 ng/mL, and the 2000 ng/mL assay uses a 6-point calibration with standards at 0, 600, 1000, 2000, 4000, and 8000 ng/mL. Table IV lists the dynamic ranges of each of the assay curves (6-9) and compares these ranges with those of the original OnLine (10-13) assays, as well as the EMIT (16) (17) (18) (19) and CEDIA (20) (21) (22) (23) assays. The dynamic range refers to the separation, in ng/mL, from the zero calibrator to the highest calibrator that a particular application uses. As Table IV indicates, the ONLINE II assays for MDN, OP 2000, and THC 50 and 100 have the largest dynamic ranges of any of the assay technologies and show considerable improvement over the original OnLine configuration.
Precision ~pical intra-and interassay precision for all four assays run on the Roche/Hitachi 917 or COBAS INTEGRA 700 are listed in Table V . The data were calculated in a quantitative mode with ng/mL units and in the qualitative mode in mA units times 10. Under Level 3 qualitative and quantitative precisions are both represented. This precision was generated on the same sets of data and demonstrates the difference in precision that can be obtained when the values are calculated in nanograms per milliliter versus the mA mode. The qualitative precision is generally seen as being better because of the way the data are expressed. When comparing precision among different assay technologies, calculations should be made in the quantitative mode because these measurements are calculated in an identical way. In the clinical and reference laboratories, DATs are most often used in the qualitative mode, and, for the purpose of providing a point of reference, the precision of the assays at the Intra-Inter-Intra-Inter-Intra-Inter-Intra-Intercutoff level was tabulated in Table V . The improved precision of the assay is largely due to the lower viscosity of the reagents. With fast kinetic homogeneous assays, one of the most important factors affecting precision is the even mixing of the reagents. By lowering the viscosity of the reaction medium, the mixing of the reagents is more rapid and impact on precision is dramatic.
For the 50-ng/mL THC-II assay, the quantitative intra-assay precision ranged from 3.9% to 5.2%, and the qualitative intraassay precision at Level 3 was 3.1%. For the BE-II assay, the quantitative intra-assay precision ranged from 2.3% to 7.5%, and the qualitative intra-assay precision at Level 3 was 1.4%. For the MDN-II assay, the intra-assay quantitative precision ranged from 2.0% to 3.8%, and the qualitative intra-assay precision at Level 3 was 1.9 %. The OP-I12000-ng/mL intra-assay quantitative assay precision ranged from 1.9% to 4.2%, and the qualitative intra-assay precision at Level 3 was 0.4%. The interassay precision for all assays was generally 1-2% higher over the 5-day period.
Clinical and analytical LODs
The clinical and analytical LODs for each of the assays on the Roche/Hitachi 917 are listed in Table VI . The clinical LOD varied from as low as 2.6 ng/mL for the THC 50 to as high as 36.6 ng/mL for the BE assay. The analytical sensitivity for all of the assays was lower than the clinical sensitivity and ranged from 2.6 ng/mL for THC to 8.2 ng/mL for cocaine. Performance on the COBAS INTEGRA 700 system was also conducted and resulted in similar values. The ratios of the cutoff to the clinical LOD (cutoff/LOD) for the ONLINE II assays ranged from 8 to 29, which indicates a substantial separation between clinically negative samples and the cutoff.
Carryover
Sample carryover for all assays was not observed, even with sample drug concentrations of 100 times the cutoff concentration. The percent carryover was 0.01% or lower for all four of the drugs evaluated in this study. This indicates that the routine maintenance used on both the Roche/Hitachi and COBAS IN-TEGRA systems is adequate to prevent carryover for these four drugs, even at extremely high concentrations of drug-containing samples.
Interferants and adulterants
Common interfering substances (Table III) and adulterants were run in all four assays and did not show any appreciable effect on the observed concentration. In general, the values did not vary by more than 10% of the expected value of spiked drug. The OP assay was not significantly affected (> 10% difference in values) by the interfering substances or adulterants tested in this study. With respect to interferants, both the THC and cocaine assays Intra-Inter-showed greater than 10% variation with 1.5% ascorbic acid. The MDN assay varied by greater III). The BE assay showed greater than 10% negative recovery difference with 10% Drano and 10% ammonia, with recoveries of 17 and 84, respectively. Finally, the MDN assay varied by greater than 10% negative recovery with 10% ammonia and 10% Drano, with values of 67% and 47%, respectively. The ONLINE II assays are generally robust to adulterants that are aimed to create false-negative samples, with some exceptions, as noted. Because the KIMS technology has a negative slope dose response curve, adulterants designed to interfere with the immunological reaction or signal will serve to create a positive response in the assay. Because a number of DAT assay technologies on the market have positive slope dose response curves, an adulterant that distorts the immunological reaction or signal will serve to create a false negative (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . It is generally only those adulterants that actually degrade the drug in the sample that will have the effect of creating a false negative in the KIMS technology.
Standard curve stability
The • 25% controls were run at intervals no further apart than one week to assess standard curve stability. The reagents were opened and kept on-board for the entire term of the study. The results of these studies conducted on the COBAS INTEGRA 700 indicate that these reagents are stable for greater that five weeks and, in some cases, greater than 10 weeks. The stability studies were usually stopped at 10 weeks for practical reasons and did not reflect failed stability. Representative stability graphs of the THC 20 and 50, BE 150/300, MDN 300, and OP 2000 are shown in Figure 3 . The THC assay was equally stable at all three cutoff points (20, 50 , and 100 ng/mL). The standard curve stability was also performed on the Roche/Hitachi 917, resuiting in similar performance, as shown in Figure 3 . These results indicate that the system is sufficiently stable, therefore calibration curves could be stored for extended periods of time and could be used with different reagent bottles within the same lot of reagents. The increased stability of ONLINE II over OnLine can be attributed to two key factors. The first is placement of the antibody on the microparticle surface and the antigen conjugate in solution. The second factor is minimizing the effect of evaporation by using components in the buffers that have less of an influence on the reaction kinetics. Both factors have led to greater stability of the reagents over the original OnLine assays.
Clinical performance
The results of the clinical comparison between ONLINE II and OnLine are shown in Table VII . At least 50 confirmed positive and 100 negative specimens were run in each assay. The results indicate that the clinical pick-up rate for the BE-II, MDN-II, and OP-II assays changed slightly. This is not unexpected because the cross-reactivities of the respective antibodies did not change appreciably, and the clinical samples contained concentrations of the drug substantially higher than the cutoff. For the THC-II assay, there was a considerable difference. The ONLINE II assay for THC gave 23% more positives at the 50 ng/mL cutoff than the original OnLine reagents without resulting in any false-positive readings. Examining the semiquantitative values of the 51 THC-containing samples showed that the new assay cross-reacted with a wider range of cannabinoids (68% increase) than did the original OnLine assay. This assay was developed with a monoclonal antibody that was designed to have broader selectivity to many of the more common THC metabolites (31) , and the findings in this study are supportive of this higher cross-reactivity.
Conclusions
The ONLINE II assays are a liquid, ready-to-use, two-reagent kit concept that no longer requires any mixing of reagents. This has served to double the throughput on the COBAS IN-TEGRA systems and has eliminated the reagent premixing associated with the Roche/Hitachi line of analyzers. The kinetics of the system allows for extended dynamic ranges of the dose response curves so that dilutions for GC-MS work can be more easily estimated. This results in a reduced number of repeats associated with semiquantitative testing. The increased dynamic ranges have also allowed multiple cutoffs to be established with one standard curve for some of the assays. The shelf-life and standard curve stability have also been improved. The viscosity of the reagents has been dramatically reduced, significantly Negatives  100 100 100  -100  100  100  100  100  100  Positives  50  37  21  -30  50  50  50  50  55  False negatives  1  14  30  -21  -0 improving the intra-and interassay precision. The new antibodies used in the cannabinoids (THC), methadone (MDN), and cocaine (BE) ONLINE II assays have increased the selectivity in the BE and MDN assays and the selectivity and sensitivity in the THC assay. The ONLINE II assay for THC assay employs a unique monoclonal antibody that was designed to have broad cross-reactivity to a wide range of cannabinoids (22) . This monoclonal was generated with a benzpyrene immunogen and is the antibody that is used in the OnLine THC ES reagent. With cannabinoidcontaining clinical samples used in this study, the 68% increase in cross-reactive cannabinoids over the original OnLine THC reagents is reflective of the broader cross-reactivity of this antibody. This higher cross-reactivity translated into a 23% increase in positive samples over the OnLine THC assay at the 50 ng/mL cutoff. The dynamic range of the ONLINE II THC assay is also significantly changed over OnLine, and the curve for the 50 and 100 ng/mL assays extends up to 300 ng/mL. The intraassay precision throughout the curve ranges between 3.1% and 5.2% across all levels (Table V) . Additionally, the standard curve stability with ONLINE II is greater than OnLine. The standard curve stability at the 20, 50, and 100 ng/mL levels was shown to be at least 68 days (Figure 3) . The stability did not fail at day 68, but the study was ended. This type of standard curve and onboard stability makes the ONLINE II reagents some of the most stable homogeneous immunodiagnostic reagents in the field.
In summary, the ONLINE II reagents represent a significantly improved system for the analysis of drugs of abuse in urine. These improvements translate into higher clinical and analytical performance that lead to higher operational efficiencies for the laboratory.
